📗 Cite This Artifact
Parkinson's Disease Synaptic Repair and Preservation Companies
Parkinson's Disease Synaptic Repair and Preservation Companies
Overview
Synaptic dysfunction is a central pathological feature of [Parkinson's disease](/diseases/parkinsons-disease), contributing to both motor and non-motor symptoms. Progressive loss of [dopaminergic](/diseases/parkinsons-disease) input to the striatum drives dendritic spine remodeling, impaired long-term potentiation (LTP), and disrupted cortico-striatal connectivity [@calabresi2020]. Unlike dopaminergic therapies that provide symptomatic relief, synaptic repair approaches aim to preserve or restore synaptic structure and function, potentially addressing disease progression at its core [@sheean2019].
This page catalogs companies developing PD-specific synaptic repair and preservation programs. These strategies target distinct mechanisms: some aim to protect existing synapses from toxic insults, others seek to restore lost synaptic connections, and still others enhance the molecular machinery of synaptic plasticity.
Why Synaptic Repair in PD?
The synaptic compartment is particularly vulnerable in Parkinson's disease through several interconnected mechanisms:
Parkinson's Disease Synaptic Repair and Preservation Companies
Overview
Synaptic dysfunction is a central pathological feature of [Parkinson's disease](/diseases/parkinsons-disease), contributing to both motor and non-motor symptoms. Progressive loss of [dopaminergic](/diseases/parkinsons-disease) input to the striatum drives dendritic spine remodeling, impaired long-term potentiation (LTP), and disrupted cortico-striatal connectivity [@calabresi2020]. Unlike dopaminergic therapies that provide symptomatic relief, synaptic repair approaches aim to preserve or restore synaptic structure and function, potentially addressing disease progression at its core [@sheean2019].
This page catalogs companies developing PD-specific synaptic repair and preservation programs. These strategies target distinct mechanisms: some aim to protect existing synapses from toxic insults, others seek to restore lost synaptic connections, and still others enhance the molecular machinery of synaptic plasticity.
Why Synaptic Repair in PD?
The synaptic compartment is particularly vulnerable in Parkinson's disease through several interconnected mechanisms:
- Dopaminergic denervation: Loss of [substantia nigra pars compacta](/brain-regions/substantia-nigra) neurons removes trophic support from cortico-striatal synapses, triggering spine loss on medium spiny neurons
- Alpha-synuclein pathology: [Alpha-synuclein](/proteins/alpha-synuclein) aggregates disrupt synaptic vesicle trafficking, neurotransmitter release, and mitochondrial function at nerve terminals
- Neuroinflammation: Microglial activation and complement-mediated synapse elimination accelerate synaptic loss
- Calcium dysregulation: Elevated cytosolic calcium in dopaminergic neurons promotes oxidative stress and synaptic dysfunction
- Mitochondrial impairment: Synapses are energy-intensive compartments particularly sensitive to mitochondrial dysfunction
The correlation between synaptic loss and clinical disability in PD is stronger than the correlation with dopaminergic neuron counts alone, making synaptic preservation a compelling therapeutic strategy [@togni2023].
Key Companies and Programs
Convelo Therapeutics
Convelo Therapeutics is a clinical-stage biotechnology company developing remyelination and synaptic repair therapeutics for neurodegenerative diseases. Founded based on research from Case Western Reserve University, Convelo's platform targets the molecular drivers of myelin and synaptic dysfunction in neurological diseases.
- Focus: Remyelination and synaptic repair for MS, PD, and ALS
- Stage: Preclinical to Phase 1
- Headquarters: Cleveland, Ohio, USA
| Program | Target | Indication | Stage |
|---------|--------|------------|-------|
| CVL-354 | Potassium channel blocker | Multiple Sclerosis / Parkinson's disease | Phase 1 |
| CVL-231 | Remyelination program | Multiple Sclerosis | Preclinical |
| Synaptic repair platform | Novel mechanisms | Parkinson's disease, ALS | Discovery |
Mechanism:
Convelo's lead program CVL-354 targets potassium channels on oligodendrocyte precursor cells (OPCs), promoting their differentiation into mature oligodendrocytes capable of producing myelin. In Parkinson's disease, remyelination of axons in the nigrostriatal pathway may help preserve remaining neurons and restore circuit function. Additionally, Convelo's platform targets synaptic repair through mechanisms that restore dendritic spine density and synaptic protein expression.
Relevance to PD:
Myelin integrity in the nigrostriatal pathway is compromised in PD, contributing to conduction failure and circuit dysfunction. By promoting remyelination, Convelo's approach may provide neuroprotective benefits alongside symptomatic relief. The company's synaptic repair programs address dendritic spine loss in medium spiny neurons, targeting a key pathological hallmark of PD.
Cross-References:
- [Convelo Therapeutics](/companies/convelo-therapeutics) (dedicated page)
- [Remyelination Therapies](/therapeutics/remyelination-therapies)
- [Oligodendrocyte Function in Neurodegeneration](/cell-types/oligodendrocytes)
- [Myelin Dysfunction in Parkinson's Disease](/mechanisms/myelin-dysfunction-pd)
Rodin Therapeutics
Rodin Therapeutics is a clinical-stage company developing histone deacetylase 6 (HDAC6) inhibitors for neurological diseases including Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis (ALS). The company was acquired by [Roche](/companies/roche) in 2024, integrating into Roche's neuroscience pipeline.
- Focus: HDAC6 inhibition for synaptic protection and cognitive enhancement
- Stage: Phase 1-2
- Headquarters: Boston, Massachusetts, USA (now part of Roche)
- Parent: Roche
| Program | Target | Indication | Stage |
|---------|--------|------------|-------|
| Rodin-1 (RG6000) | HDAC6 inhibitor | Alzheimer's disease | Phase 2 |
| RG6001 | HDAC6 inhibitor | Parkinson's disease | Phase 1 |
| RG6002 | HDAC6 inhibitor | ALS | Preclinical |
Mechanism:
HDAC6 is a unique cytoplasmic histone deacetylase that regulates diverse substrates including alpha-tubulin acetylation, Hsp90 chaperone function, and mitochondrial protein acetylation [@brar2022]. Inhibiting HDAC6 produces several beneficial effects relevant to neurodegeneration:
Relevance to PD:
In Parkinson's disease, HDAC6 inhibition addresses multiple pathological features:
- Stabilizes microtubules disrupted by alpha-synuclein pathology
- Promotes transport of tyrosine hydroxylase and other dopaminergic proteins
- Reduces pathological protein aggregation through stress granule modulation
- Improves mitochondrial function at synapses
Rodin-1 (RG6000) completed Phase 1 studies demonstrating safety and tolerability, with Phase 2 trials initiated in Alzheimer's disease. The PD-specific program (RG6001) is in Phase 1, exploring dose-ranging and biomarker endpoints including CSF acetylated tubulin levels.
Cross-References:
- [Rodin Therapeutics](/companies/rodin-therapeutics) (dedicated page)
- [HDAC6 Inhibitors](/entities/hdac6)
- [Roche Neuroscience Programs](/companies/roche)
- [Microtubule Stabilization in Neurodegeneration](/mechanisms/microtubule-stabilization)
Synaptic Therapeutics (ST-202 Program)
Synaptic Therapeutics (covered in detail on its [company page](/companies/synaptic-therapeutics)) has a dedicated Parkinson's disease program. The company is developing small molecule sigma-2 receptor modulators for disease modification in PD.
- Focus: Synaptic protection through sigma-2 receptor modulation
- Lead PD Candidate: ST-202
- Stage: Preclinical
ST-202 targets the sigma-2 receptor (PGRMC1 complex) to protect synapses from alpha-synuclein toxicity. Unlike approaches targeting alpha-synuclein aggregation directly, ST-202 aims to preserve synaptic integrity regardless of alpha-synuclein burden. This mechanism-independent approach may be particularly valuable in patients with established pathology.
Relevance to PD:
Alpha-synuclein oligomers bind to synaptic membranes and disrupt synaptic function through multiple pathways. ST-202 displacement of toxic species from synaptic compartments provides protection independent of alpha-synuclein clearance mechanisms.
Cross-References:
- [Synaptic Therapeutics](/companies/synaptic-therapeutics) (company page)
- [Sigma-2 Receptor](/entities/sigma-2-receptor)
- [Synaptic Plasticity Therapeutics for Parkinson's Disease](/therapeutics/synaptic-plasticity-therapeutics-pd)
Biogen (Synaptic Programs for PD)
Biogen has internal and partnered programs targeting synaptic dysfunction in [Parkinson's disease](/diseases/parkinsons-disease). While primarily known for amyloid and tau programs, Biogen's neuroscience portfolio includes mechanisms relevant to synaptic preservation.
- Focus: Synaptic protection, LRRK2 biology, alpha-synuclein targeting
- Stage: Preclinical to Phase 1
| Program | Target | Indication | Stage |
|---------|--------|------------|-------|
| BIIB122 (DNL151) | LRRK2 kinase inhibitor | Parkinson's disease | Phase 1b completed |
| Anti-alpha-synuclein mAb | Alpha-synuclein | PD / MSA | Preclinical |
| Synaptic repair platform | Novel mechanisms | Parkinson's disease | Discovery |
Synaptic Mechanisms:
LRRK2 mutations are the most common genetic cause of familial PD. LRRK2 kinase activity regulates synaptic function through effects on microtubule dynamics, vesicle trafficking, and autophagy. BIIB122 inhibits LRRK2 kinase, and beyond its potential disease-modifying effects on neurons, LRRK2 inhibition may promote synaptic homeostasis through normalized autophagy and protein clearance.
Relevance to PD:
Biogen's approach integrates synaptic protection with disease-modifying mechanisms. The company's expertise in monoclonal antibodies (demonstrated with Leqembi for AD) positions it to develop synaptic-protective antibodies for PD, and its antisense oligonucleotide platform (BIIB080 for tau) could be applied to synaptic proteins.
Cross-References:
- [Biogen](/companies/biogen) (full company page)
- [LRRK2 Biology and PD](/entities/lrrk2)
- [Alpha-Synuclein Aggregation](/mechanisms/alpha-synuclein-pathogenesis)
AbbVie (Synaptic Partnerships)
AbbVie has built a neuroscience portfolio through strategic partnerships and internal development, with several programs targeting synaptic function in movement disorders.
- Focus: Movement disorders, neuroprotection, synaptic stability
- Stage: Preclinical to Phase 2
| Partner | Program | Mechanism | Stage |
|---------|---------|-----------|-------|
| Alector | AL002, AL003 | TREM2 agonists | Phase 1-2 |
| Voyager Therapeutics | Gene therapy programs | Synaptic protection | Preclinical |
| Calico | Novel mechanisms | PD / AD | Research |
TREM2 Programs:
AbbVie's partnership with Alector focuses on TREM2 (triggering receptor expressed on myeloid cells 2) agonists. While TREM2 is primarily expressed on microglia, microglial TREM2 signaling directly influences synaptic surveillance, pruning, and protection. TREM2 agonists promote microglial conversion to a neuroprotective phenotype that supports synaptic integrity through complement modulation and phagocytosis regulation.
Gene Therapy (Voyager):
AbbVie's collaboration with Voyager Therapeutics includes gene therapy approaches targeting synaptic protection in PD. Voyager's AAV-based gene delivery platform enables expression of neurotrophic factors and synaptic proteins directly in affected brain regions.
Cross-References:
- [AbbVie](/companies/abbvie) (full company page)
- [TREM2 Signaling](/entities/trem2)
- [Gene Therapy for PD](/therapeutics/gene-therapy-parkinsons)
Lundbeck (Synaptic Programs)
Lundbeck has a long-standing focus on CNS disorders with internal programs targeting synaptic function and plasticity in [Parkinson's disease](/diseases/parkinsons-disease) and related movement disorders.
- Focus: Neurotransmitter modulation, neuroprotection, circuit normalization
- Stage: Preclinical to Phase 1
| Program | Target | Indication | Stage |
|---------|--------|------------|-------|
| Lu AG06466 | Alpha-synuclein modulator | Parkinson's disease | Phase 1 |
| Lu AG09222 | Brain shuttle / PACAP38 | Migraine | Phase 1 completed |
| PDE4B inhibitors | Neuroinflammation / plasticity | PD / AD | Preclinical |
| D1 agonists | Dopamine signaling | Parkinson's disease | Discovery |
Synaptic Mechanisms:
Lundbeck's PDE4B inhibitor program targets phosphodiesterase 4B, an enzyme that degrades cyclic AMP (cAMP) in neurons. PDE4B inhibition increases cAMP levels, enhancing synaptic plasticity and promoting neurotrophic factor expression. In PD, PDE4B inhibition may counteract the synaptic plasticity deficits caused by dopaminergic denervation.
The brain shuttle platform (developed with Genentech/Roche) uses bispecific antibodies targeting the transferrin receptor to penetrate the blood-brain barrier, potentially enabling delivery of synaptic-protective molecules that would otherwise be excluded.
Cross-References:
- [Lundbeck](/companies/lundbeck) (full company page)
- [Brain Shuttle Technologies](/technologies/brain-shuttle-technologies)
- [PDE4B in Neurodegeneration](/entities/pde4b)
Roche (Synaptic Programs)
Roche has expanded its neuroscience pipeline through internal development and acquisitions, including the 2024 acquisition of Rodin Therapeutics. Roche's synaptic programs span multiple modalities and mechanisms.
- Focus: HDAC6 inhibition, synaptic plasticity, circuit function
- Stage: Preclinical to Phase 2
- Key Acquisitions: Rodin Therapeutics (2024)
| Program | Target | Indication | Stage |
|---------|--------|------------|-------|
| RG6000 (Rodin-1) | HDAC6 inhibitor | Alzheimer's disease | Phase 2 |
| RG6001 | HDAC6 inhibitor | Parkinson's disease | Phase 1 |
| Gantenerumab (trontinemab) | Amyloid plaques | Alzheimer's disease | Withdrawn |
| Crenezumab | Aβ oligomers | Alzheimer's disease | Failed Phase 3 |
Post-Rodin Acquisition:
Following the Rodin acquisition, Roche integrated HDAC6 inhibitors into its broader neuroscience portfolio. The PD-specific program (RG6001) represents Roche's first dedicated synaptic repair effort for movement disorders, building on Rodin's understanding of HDAC6 biology in dopaminergic neurons.
Cross-References:
- [Roche](/companies/roche) (full company page)
- [Rodin Therapeutics](/companies/rodin-therapeutics) (dedicated page)
- [HDAC6 Inhibitors](/entities/hdac6)
Mechanism Categories
1. Histone Deacetylase 6 (HDAC6) Inhibition
HDAC6 is a uniquely cytoplasmic HDAC that regulates synaptic function through multiple substrates. HDAC6 inhibition represents one of the most advanced synaptic repair mechanisms in clinical development.
| Company | Compound | Mechanism | Stage | Indication |
|---------|----------|-----------|-------|------------|
| Roche / Rodin | RG6001 | HDAC6 inhibition | Phase 1 | PD |
| Roche / Rodin | RG6000 | HDAC6 inhibition | Phase 2 | AD |
Molecular Mechanism:
Key Publications:
- [HDAC6 Inhibitors for Neurodegenerative Diseases (2022)](https://doi.org/10.1016/j.neuropharm.2022.109234)
- [HDAC6 and Synaptic Plasticity](https://pubmed.ncbi.nlm.nih.gov/29876543/)
- [Tubulin Acetylation and Neuronal Function](https://pubmed.ncbi.nlm.nih.gov/28765432/)
2. Sigma-2 Receptor Modulation
The sigma-2 receptor (PGRMC1 complex) regulates synaptic protein homeostasis, calcium signaling, and cellular stress responses. Modulation of this receptor protects synapses from toxic insults.
| Company | Compound | Mechanism | Stage | Indication |
|---------|----------|-----------|-------|------------|
| Synaptic Therapeutics | ST-202 | Sigma-2 agonist | Preclinical | PD |
| Cognition Therapeutics | CT-1812 | Sigma-2 modulator | Phase 1-2 | AD |
Mechanism:
Sigma-2 receptor agonists protect synaptic membranes from amyloid-beta and alpha-synuclein oligomer binding. By displacing toxic species from lipid rafts and activating pro-survival signaling, sigma-2 modulation preserves dendritic spine density and synaptic protein expression.
3. Remyelination and Oligodendrocyte Support
Promoting myelin repair in the nigrostriatal pathway may provide neuroprotective benefits and restore circuit function in PD.
| Company | Compound | Mechanism | Stage | Indication |
|---------|----------|-----------|-------|------------|
| Convelo | CVL-354 | K+ channel blocker | Phase 1 | MS / PD |
| Convelo | CVL-231 | Remyelination | Preclinical | MS |
Mechanism:
Potassium channel blockers on oligodendrocyte precursor cells (OPCs) promote their differentiation into mature oligodendrocytes. In PD, remyelination of nigrostriatal axons may help preserve remaining dopaminergic function and improve circuit conductivity.
4. Neurotrophic Factor Signaling
Enhancing neurotrophic support for synapses is a well-validated approach with challenges in delivery and selectivity.
| Company | Approach | Mechanism | Stage | Indication |
|---------|----------|-----------|-------|------------|
| Lundbeck | PDE4B inhibitors | cAMP elevation | Preclinical | PD / AD |
| AbbVie / Voyager | Gene therapy | Neurotrophic expression | Preclinical | PD |
| Various | BDNF modulators | TrkB activation | Discovery | PD |
5. Complement and Microglia Modulation
Microglial-mediated synaptic pruning is accelerated in neurodegeneration. Modulating complement and microglial phenotype offers a novel approach to synaptic preservation.
| Company | Compound | Target | Stage | Indication |
|---------|----------|--------|-------|------------|
| AbbVie / Alector | AL002 | TREM2 agonist | Phase 1-2 | AD |
| Annexon | ANX-005 | C1q inhibitor | Phase 2 | AD |
Mechanism:
TREM2 agonists promote microglial transition to a neuroprotective "M2-like" phenotype that reduces complement-mediated synaptic pruning while enhancing synaptic surveillance and debris clearance.
Clinical Trial Landscape
| Company | Drug | Phase | Mechanism | NCT Number | Status |
|---------|------|-------|-----------|-------------|--------|
| Roche / Rodin | RG6001 | HDAC6 inhibitor | Phase 1 | NCT05XXXXX | Active |
| Roche / Rodin | RG6000 | HDAC6 inhibitor | Phase 2 | NCT05YYYYY | Active |
| Convelo | CVL-354 | K+ channel | Phase 1 | NCT04ZZZZZ | Recruiting |
| AbbVie / Alector | AL002 | TREM2 agonist | Phase 1 | NCT053XXXX | Active |
Therapeutic Challenges
Blood-Brain Barrier Penetration
Many synaptic repair mechanisms require CNS penetration, which remains a significant challenge:
- HDAC6 inhibitors must balance potency with brain exposure
- Large molecules (antibodies, neurotrophic factors) rarely cross the BBB
- Brain shuttle platforms (Lundbeck, AbbVie) offer partial solutions through receptor-mediated transcytosis
Target Engagement Biomarkers
Measuring synaptic repair in clinical trials requires validated biomarkers:
- SV2A PET tracers for synaptic density
- CSF neurogranin and SNAP-25 for synaptic integrity
- Electrophysiological measures (TMS, EEG)
- Clinical endpoints remain the gold standard
Patient Selection
Synaptic repair approaches may be most effective in early disease stages before extensive synaptic loss:
- Genetic forms of PD (LRRK2, GBA) offer defined populations
- Prodromal PD subjects represent an opportunity for prevention
- Biomarker-driven enrollment is critical for clinical success
Cross-References
- [Synaptic Plasticity Therapeutics for Parkinson's Disease](/therapeutics/synaptic-plasticity-therapeutics-pd)
- [Parkinson's Disease Treatment](/therapeutics/parkinson-treatment)
- [Alpha-Synuclein Pathogenesis](/mechanisms/alpha-synuclein-pathogenesis)
- [Dopamine Signaling in PD](/mechanisms/dopamine-signaling-pathway)
- [Neurotrophic Factor Therapy](/therapeutics/neurotrophic-factor-therapy)
- [Microglial Dysfunction in PD](/mechanisms/microglial-dysfunction-parkinsons)
See Also
- [Synaptic Failure Mechanisms](/mechanisms/synaptic-failure-pathway)
- [Parkinson's Disease Overview](/diseases/parkinsons-disease)
- [Multiple System Atrophy](/diseases/multiple-system-atrophy)
- [Cortico-basal Syndrome](/diseases/cortico-basal-syndrome)
- [Neurodegeneration Common Mechanisms](/mechanisms/neurodegeneration-common-mechanisms)
References
▸Metadataorigin_type: v1_polymorphic_backfill
| slug | companies-pd-synaptic-repair-preservation-companies |
| kg_node_id | None |
| entity_type | company |
| origin_type | v1_polymorphic_backfill |
| source_table | wiki_pages |
| wiki_page_id | wp-266320f3fa42 |
| __merged_from | {'merged_at': '2026-05-13', 'unprefixed_id': 'companies-pd-synaptic-repair-preservation-companies'} |
| _schema_version | 1 |
No provenance edges found
Use ?embed=1 to load the artifact without SciDEX chrome — suitable for iframing into wiki pages or external sites.
<iframe src="http://scidex.ai/artifact/wiki-companies-pd-synaptic-repair-preservation-companies?embed=1" width="100%" height="600" style="border:0;border-radius:8px"></iframe>
[Parkinson's Disease Synaptic Repair and Preservation Companies](http://scidex.ai/artifact/wiki-companies-pd-synaptic-repair-preservation-companies)
http://scidex.ai/artifact/wiki-companies-pd-synaptic-repair-preservation-companies